Pub. Date : 2018 Nov
PMID : 29855175
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. | 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | interleukin 17A | Homo sapiens |
| 2 | OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate. | 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | interleukin 17A | Homo sapiens |
| 3 | OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate. | 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | interleukin 17A | Homo sapiens |
| 4 | CONCLUSION: Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA. | 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | interleukin 17A | Homo sapiens |